Last Updated : November 4, 2022
Details
Generic Name:
abaloparatide
Project Status:
Withdrawn
Therapeutic Area:
Osteoporosis, postmenopausal women
Manufacturer:
Paladin Labs Inc.
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0744-000
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of osteoporosis in postmenopausal women at high risk of fracture or who have failed on other available osteoporosis therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of osteoporosis in postmenopausal women at high risk of fracture or who have failed or are intolerant to other available osteoporosis therapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2 |
|
|---|---|
| Call for patient/clinician input open | July 04, 2022 |
| Call for patient/clinician input closed | August 26, 2022 |
| Clarification:
- Patient input submission received from Osteoporosis Canada |
|
| Submission received | August 02, 2022 |
| Submission accepted | August 19, 2022 |
| Review initiated | August 22, 2022 |
| Clarification:
Voluntarily withdrawn by the sponsor on 04 Nov 2022 |
|
Last Updated : November 4, 2022